Wolfgang is Managing Partner of Carlyle Global Advisors after a successful career as serial entrepreneur in healthcare. He has developed a network of relationships with accomplished family offices in both the United States and internationally that share a passion for impact Investing and philanthropy in the life sciences and whom he advises from time to time in healthcare related investments. He has successfully helped build and exited from several life science companies to-date principally in the areas of neurological disease, cardiovascular disease and oncology related innovation. Wolfgang holds a M.S. in Physics from University of Gӧttingen and a PhD from Technical University Hamburg-Harburg, both in Germany. Wolfgang is also an active angel investor with Keiretsu in Palo Alto, CA.
Federico Goodsaid, PhD, is a regulatory strategy consultant at Regulatory Pathfinders and Ariana Data Intelligence. As Principal Consultant at Regulatory Pathfinders LLC, he focuses on regulatory strategy and pathways required for precisionmedicine therapeutic and diagnostic products. At Ariana, the SVP of Regulatory Affairs is responsible for translating patient selection and surrogate biomarkers into successful regulatory submissions for therapeutic and diagnostic products. He was CEO of MBQ Pharma (2018-2022), a biotech company licensing IP developed at the University of Puerto Rico. He led MBQ Pharma to FDA acceptance in 2022 of the IND for the Phase 1 study of MBQ-167 in advanced metastatic breast cancer. Prior to this appointment, he was the Senior Vice President for Product Development and Regulatory Affairs at TOMA Biosciences (2015-2017), where he worked on the preclinical and clinical development and regulatory submissions for a 130-gene targeted NGS oncology panel. His previous work at Vertex (2011-2015) focused on therapeutic product submissions in cystic fibrosis which led to the first in-vitro surrogate label expansion for Kalydeco. He was previously Associate Director for Operations in Genomics and Biomarker Qualification Coordinator at the Office of Clinical Pharmacology/Office of Translational Sciences/ Center for Drug Evaluation and Research/ U.S. FDA (2004-2011), working on the regulatory application and development of genomics and biomarkers. Before joining the FDA, he served as Head of the Molecular Toxicology Group at the Schering-Plough Research Institute (2000-2004), Senior Staff Scientist at Applied Biosystems (1996-2000), where he developed the original TaqMan and SYBR qPCR reagents, Manager of TPD Consumables at Abbott Diagnostics (1992-1996), for the development and launch of the AxSYM Instrument, and at Pacific Biotech (1990-1992), where he worked on the development of the first commercially successful one-step immunodiagnostic pregnancy test. Following his Ph.D. from Yale University in Molecular Biophysics and Biochemistry, he was trained as a Muscular Dystrophy Association Postdoctoral Fellow at Cornell University in Ithaca and at Washington University in St. Louis.
For the past 26 years, Krinx has been delivering results with leadership roles in commercial healthcare operations, business development and sales primarily in the areas of cardiovascular disease, oncology and clinical wellness. From being a sales manager/influencer for a mid-size pharma company KOS (acquired by Abbot for $1.5B), advising the C-Suite of hospital CEOs on sales strategy for the largest private hospital organization in the US (HCA) and to building the clinical sales/operations department from the ground up at Boston Heart (acquired by Eurofins for $200M+), where he worked together with CEO, Wolfgang Daum, he has made an impact on organizations at all levels. Krinx grew up in Dallas, TX and attended the University of Texas in Austin where he received his BBA in Marketing from the McCombs School of Business.
Dr. Andersen has received numerous awards including a Brookdale National Fellowship, a Glenn Award for Research in Biological Mechanisms in Aging, a Senior Ellison Scholarship, and an Award from the XIX World Congress of Parkinson’s disease (PD). She was elected a fellow of the Society for Free Radical Biology and Medicine in 2013 and received a Parkinson’s Pioneer Award from the National Parkinson’s Foundation in 2015. She serves on several national and international advisory boards and grant reviewing committees and as an editor for several journals in the field. The Andersen Lab concentrates on understanding the underlying age-related processes driving neurodegenerative diseases such as Alzheimer’s and Parkinson’s. The laboratory’s recent work is towards determining the role of a well-known aging process known as cellular senescence in age-related neurodegenerative diseases. Current work in the laboratory is towards understanding the precise mechanisms driving this process in the diseased brain towards the identification of novel therapeutics. Julie Andersen received her PhD from the Department of Biological Chemistry, UCLA School of Medicine. She conducted her postdoctoral training in the Neurogenetics Unit at Massachusetts General Hospital East in the Department of Neurology at the Harvard Medical School. She joined the School of Gerontology at the University of Southern California in 1992 as Assistant Professor where she held the Paul F. Glenn Chair in Molecular and Cellular Gerontology. She was promoted to Associate Professor at USC in 1999. In 2000, she joined the Buck Institute where she was promoted in 2005 to the position of Full Professor.
Dr. Lithgow received his PhD from the University of Glasgow and obtained further training at Ciba Geigy AG in Basel, Switzerland, and at the University of Colorado. He established his lab studying the biology of aging at the University of Manchester, England, before moving it to the Buck Institute in 2000.Dr. Lithgow has been recognized for his research with a Glenn Award for Research in Biological Mechanisms of Aging, a senior scholarship from the Ellison Medical Foundation, and the Tenovus Award for Biomedical Research. He has served on many national advisory panels in both the United Kingdom and the United States, including the National Institute on Aging’s Board of Scientific Councilors, and has served as the chair of biological sciences at the Gerontology Society of America.Dr. Lithgow has partnered with a series of biotechnology companies in sponsored research agreements and has strong collaborations in preclinical aging research on diseases such as osteoporosis and Parkinson’s disease.
Manish Chamoli, PhD - Research Scientist at the Buck
Dr. Manish Chamoli is a Research Scientist at the Buck Institute for Research on Aging, specializing in aging biology. He holds a Master’s in Biotechnology (Hons.) and a PhD in Aging Biology from the National Institute of Immunology, India. His initial research focused on the molecular mechanisms underlying dietary restriction-mediated longevity, a project supported by the Department of Biotechnology, Government of India. He then transitioned to the Lithgow Lab at the Buck Institute as a postdoctoral fellow, funded by the prestigious Larry L. Hillblom Fellowship, where his work centered around small molecule screening and protein homeostasis. Progressing to the role of Research Scientist, he established a successful collaboration with the Andersen Lab to advance drug discovery efforts, particularly targeting mitochondrial quality control in aging and age-related diseases. His significant contributions to the field are evident in his strong publication record in leading scientific journals, including Science, Nature Communications, PNAS, Cell Metabolism, Aging Cell, and eLife. He has also presented at esteemed scientific conferences, such as the American Aging Association Annual Meeting and the Gordon Research Conference.”
We identified novel compounds that are strong Mitophagy Inducing Compounds (MIC)
These compounds may have a significant role on disease and aging.